Bluejay begins phase 3 trial of brelovitug for hepatitis D - PharmaTimes First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

#Bluejay #BluejayTherapeutics #phase3trial #brelovitug #BJT778 #hepatitisD #AZURE2study #CHD #hepatitisDvirus #cirrhosis #livercancer #viralhepatitis #liverdisease #BreakthroughTherapydesignation #FDA #PRIMEdesignation #Orphanstatus #OrphanDrug #EMA
pharmatimes.com/news/bluejay...

Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia - OncoDaily Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia / Arthur T. Sands, cancer, EMA PRIME Designation,

Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia

oncodaily.com/drugs/nurix-...

#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health